摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-acetyl-2-methylbenzoic acid | 1216048-89-3

中文名称
——
中文别名
——
英文名称
5-acetyl-2-methylbenzoic acid
英文别名
——
5-acetyl-2-methylbenzoic acid化学式
CAS
1216048-89-3
化学式
C10H10O3
mdl
——
分子量
178.188
InChiKey
VZZNPMYNUNXWSC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    355.0±30.0 °C(Predicted)
  • 密度:
    1.189±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    54.4
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-acetyl-2-methylbenzoic acid 在 sodium persulfate 、 silver nitrate 、 Selectfluor 作用下, 以 乙腈 为溶剂, 反应 3.0h, 以65%的产率得到5-acetyl-2-(difluoromethyl)benzoic acid
    参考文献:
    名称:
    银催化的苯甲酰C的氧化活化。用于合成二氟甲基化芳烃的氢键
    摘要:
    已经开发了一种温和的催化方法,该方法通过活化苄基CH键形成二氟甲基化的芳烃。利用的AgNO 3作为催化剂时,与不同的官能团的各种芳烃经历的苄型C活化/氟化 H键可与市售的Selectfluor试剂如氟的在水溶液中的源极。该反应操作简单,适用于克级合成。
    DOI:
    10.1002/anie.201400225
  • 作为产物:
    描述:
    3,4-二甲基苯乙酮氧气 、 cobalt(II) diacetate tetrahydrate 、 1,3,5-三羟基-1,3,5-三嗪-2,4,6(1H,3H,5H)-三酮 作用下, 以 溶剂黄146 为溶剂, 120.0 ℃ 、101.33 kPa 条件下, 反应 6.0h, 生成 5-acetyl-2-methylbenzoic acid4-乙酰基-2-甲基苯甲酸
    参考文献:
    名称:
    带有各种氧的带有各种官能团的苯乙酮选择性氧化为苯甲酸衍生物
    摘要:
    通过使用N,N',N''-三羟基异氰尿酸(THICA)/乙酸钴(II)[Co(OAc )2 ]和THICA / Co(OAc)2 /乙酸锰(II)[Mn(OAc)2 ]。例如,4-甲基苯乙酮被分子氧选择性地氧化为THICA / Co(OAc)2氧化为4-乙酰基苯甲酸(85%),被Mn(OAc)2氧化为4-甲基苯甲酸(93%),而对苯二甲酸被用THICA / Co(OAc)2 / Mn(OAc)2以93%的比例获得催化系统。有趣的是,芳香环上的乙酰基可通过极少量的Mn(OAc)2有效地转化为相应的羧酸,并且本方法提供了通向常规常规方法难以制备的乙酰基苯甲酸的通用途径方法。
    DOI:
    10.1002/adsc.200900099
点击查看最新优质反应信息

文献信息

  • Benzamide derivative
    申请人:Koyano Hiroshi
    公开号:US20070123493A1
    公开(公告)日:2007-05-31
    To provide compounds which have high angiogenesis inhibiting activity, and are useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, for example, cancer and cancer metastasis, methods for producing the compounds, intermediate compounds useful for their production, and pharmaceutical compositions containing these compounds. The present invention provides compounds of formula (II), or prodrugs thereof, or pharmaceutically acceptable salts of the compounds or the prodrugs, and pharmaceuticals, and pharmaceutical compositions containing these compounds: where A 1 is C—X 1 or N; Q 1 is —A 2 ═A 3 —, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; Q 2 is —A 4 ═A 5 —, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; provided that Q 1 and Q 2 are not heteroatoms at the same time; A 2 is C—X 2 or N, A 3 is C—X 3 or N, A 4 is C—X 4 or N, and A 5 is C—X 5 or N; Y is C 1-6 alkyl, C 3-9 cycloalkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 1-6 alkoxy, C 2-7 alkenyloxy, C 2-7 alkynyloxy, or C 1-6 alkylthio; Z is a hydrogen atom, hydroxy, C 1-6 alkyl, C 3-9 cycloalkyl, or —NR 1 R 2 ; and L is selected from the formula:
    提供具有高抑制血管生成活性的化合物,可用作治疗和预防涉及病理性血管生成的疾病的药物,例如癌症和癌症转移,以及生产这些化合物的方法,用于它们的生产的中间体化合物,以及含有这些化合物的药物组合物。本发明提供以下化合物的配方(II),或其前药,或该化合物或前药的药学上可接受的盐,以及含有这些化合物的药物和药物组合物:其中A1为C-X1或N; Q1为-A2═A3-,或从-O-,-S-和-N(R10)中选择的杂原子; Q2为-A4═A5-,或从-O-,-S-和-N(R10)中选择的杂原子; 前提是Q1和Q2不同时为杂原子; A2为C-X2或N,A3为C-X3或N,A4为C-X4或N,A5为C-X5或N; Y为C1-6烷基,C3-9环烷基,C2-7烯基,C2-7炔基,C1-6烷氧基,C2-7烯氧基,C2-7炔氧基或C1-6烷硫基; Z为氢原子,羟基,C1-6烷基,C3-9环烷基或-NR1R2; L从以下公式中选择:
  • BENZAMIDE DERIVATIVE
    申请人:KOYANO Hiroshi
    公开号:US20100179326A1
    公开(公告)日:2010-07-15
    Compounds having high angiogenesis inhibiting activity useful as agents for effective treatment and prevention of diseases involving pathologic angiogenesis, e.g. cancer and cancer metastasis, are of formula (II), where A 1 is C—X 1 or N; Q 1 is -A 2 =A 3 -, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; Q 2 is -A 4 =A 5 -, or a heteroatom selected from —O—, —S—, and —N(R 10 )—; provided that Q 1 and Q 2 are not heteroatoms at the same time; A 2 is C—X 2 or N, A 3 is C—X 3 or N, A 4 is C—X 4 or N, and A 5 is C—X 5 or N; Y is C 2-6 alkyl, C 3-9 cycloalkyl, C 2-7 alkenyl, C 2-7 alkynyl, C 2-6 alkoxy, C 2-7 alkenyloxy, C 2-7 alkynyloxy, or C 1-6 alkylthio; Z is a hydrogen atom, hydroxy, C 1-6 alkyl, C 3-9 cycloalkyl, or —NR 1 R 2 ; and L is selected from the formula:
    具有高抑制血管新生活性的化合物,可用作治疗和预防涉及病理性血管新生的疾病的有效药物,例如癌症和癌症转移,其化学式为(II),其中A1为C-X1或N;Q1为-A2=A3-,或从-O-,-S-和-N(R10)中选择的杂原子;Q2为-A4=A5-,或从-O-,-S-和-N(R10)中选择的杂原子;前提是Q1和Q2不同时为杂原子;A2为C-X2或N,A3为C-X3或N,A4为C-X4或N,A5为C-X5或N;Y为C2-6烷基,C3-9环烷基,C2-7烯基,C2-7炔基,C2-6烷氧基,C2-7烯氧基,C2-7炔氧基或C1-6烷基硫;Z为氢原子,羟基,C1-6烷基,C3-9环烷基或-NR1R2;L从以下公式中选择:
  • Iron/photoredox dual catalysis for acyl nitrene-based C–O bond formation towards phthalides
    作者:Zhide Zhang、Yangling Deng、Ming Hou、Xiaojing Lai、Meng Guan、Fengzhi Zhang、Rui Qi、Guanyinsheng Qiu
    DOI:10.1039/d2cc04917a
    日期:——
    iron/photoredox dual-catalyzed acyl nitrene formation and the use of acyl nitrene in constructing various C–O bonds towards phthalides. The developed reaction starts from N-methoxyl-2-alkylbenzamides. Mechanism surveys suggest the reaction involves iron nitrene-based hydrogen atom abstraction (HAA), radical-polar crossover and O-nucleophilic SN1. Distinctively, the often-reported radical rebound in previous publications
    本文描述了铁/光氧化还原双催化酰基氮烯的形成以及酰基氮烯在构建各种 C-O 键中对苯酞的应用。开发的反应从N -methoxyl-2-alkylbenzamides 开始。机理调查表明,该反应涉及基于铁氮烯的氢原子提取 (HAA)、自由基-极性交叉和O-亲核 S N 1。值得注意的是,未观察到以前出版物中经常报道的自由基反弹。该反应代表了基于酰基氮烯的苯酞合成的第一个例子。此外,它还作为合成3-丁基苯酞(NBP)、沙利度胺、Pomalyst和Otezia等市售药物的补充剂。
  • JP5743418
    申请人:——
    公开号:——
    公开(公告)日:——
  • Synthesis of aryl N-acylurea from aryl isocyanates or aryl carbodiimides for use as intermediate in novel sequential self-repetitive reaction (SSRR) to form amides, amide-imides and their polymers
    申请人:Dai Shenghong A.
    公开号:US20070282078A1
    公开(公告)日:2007-12-06
    Disclosed is a process for synthesizing an aryl N-acylurea in both high selectivity and high yield, comprising reacting an aryl carbodiimide with a carboxylic acid under mild conditions. Thermolysis of N-acylureas at above about 120° C. gives amides and isocyanates, and the latter will undergo the repetitive reaction sequences in the presence of a carbodiimide catalyst. Based on this unique model, a sequential self-repetitive reaction (SSRR) is also developed in a versatile manner for converting aryl carbodiimides into amides, polyamides, polyamide-imides and polyamide-imide elastomers.
查看更多